Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound could help preterm babies breathe easier, faster

NCT ID NCT07442669

Diagnosis Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This study tests whether a lung ultrasound score can help doctors decide faster when to give surfactant—a medicine that helps babies' lungs work—to preterm infants with respiratory distress. Researchers will include 100 babies born between 27 and 34 weeks who need breathing support. If the ultrasound shows severe lung issues, surfactant is given through a thin tube. The goal is to shorten the time to treatment and reduce the need for a breathing machine.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lung ultrasound
What this could lead to
If successful, this could make lung ultrasound a standard tool to quickly identify which preterm babies need surfactant, potentially reducing breathing complications.
What could go wrong
This is a small pilot study, so results may not apply to all hospitals. The ultrasound score may not reliably predict who needs treatment, and the study hasn't started yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

27 to 34 weeks

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inborn at 27 0/7 to 34 6/7 weeks of gestational age * Spontaneously breathing at birth but requiring non-invasive respiratory support * RDS diagnosed on chest x-ray (diffuse, bilateral, fine granular opacities in lungs, air bronchograms) or were at risk of developing RDS Exclusion Criteria: * Outborn * Endotracheal intubation in the delivery room or within 2 hours of life * Surfactant in the delivery room as part of advanced resuscitation * Presence of major congenital malformations or chromosomal anomalies * Hydrops fetalis * Inherited disorders of metabolism * Air leak syndrome (pneumothorax, pneumomediastinum) prior to surfactant administration, congenital diaphragmatic hernia, congenital pneumonia, meconium aspiration syndrome * Infants in extremis not expected to survive

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Respiratory distress syndrome in premature infant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyspnea newborn respiratory distress syndrome respiratory distress syndrome in premature infants Respiratory Distress Syndrome, Newborn

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Respiratory distress syndrome in premature infant Respiratory distress syndrome, newborn

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hackensack Univeristy Medical Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.